CD274 and neoplasm: The discovery that tumor immune evasion promotes NACT chemoresistance via the programed death-1 (PD-1)/PD ligand 1 (PD-L1) inhibitory axis [9, 10] has provided substantial evidence supporting the use of NACT in combination with anti-PD-L1/PD-1 agents for LACC.